| 영문 | systemic lupus erythematosus | 한글 | 전신홍반루푸스 |
|---|---|---|---|
| 설명 | 전신 자가면역병의 대표적 병이다. 여성에게 압도적으로 많고, 10~39세까지가 70%를 차지한다. 원인은 잘 모르나 자가면역 조절기능에 장애가 있는 것으로 생각된다. 유전요인, 호르몬의 영향, 환경요소가 종합적으로 보조 T세포와 B세포를 활성화시켜서 여러 가지 자가항체들, 즉 천연 DNA, 이중가닥 DNA, 외가닥 DNA, RNA, 핵단백질 등과 같은 핵 항원에 대한 항체, 비핵항원에 대한 여러 가지 항체가 쏟아져 나온다. 이 중 이중가닥 DNA를 포함한 순환면역복합체가 콩팥에 침착하여 손상을 일으키는데 관여한다. DNA와 여러 가지 세포성분에 대한 자가면역질환으로 전콩팥기를 침범하여 염증을 일으킨다. 여러 자가항원에 대한 면역반응에 의한 항체의존성 면역반응과 면역복합체 반응으로 토리콩팥염, 혈관염, 관절염 및 빈혈을 동반한다. |
||
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
|---|---|
| PI | first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;... |
| DLE | delayed light emission; dialyzable leukocyte extract; discoid lupus erythematosus; disseminated lupu... |
| ESI | elastase-specific inhibitor; enzyme substrate inhibitor; epidural steroid injection |
| PTI | pancreatic trypsin inhibitor; persistent tolerant infection; Pictorial Test of Intelligence; placent... |
| ACE inhibitor | angiotensin converting enzyme inhibitor |
|---|---|
| BILAG | British Isles Lupus Assessment Group |
| DPLN | Diffuse proliferative lupus nephritis |
| DLE | Discoid Lupus Erythematosus |
| LAC | Lupus AntiCoagulant |
| lupus coagulation inhibitor | An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications. (12 Dec 1998) |
|---|---|
| panniculitis, lupus erythematosus | A type of lupus erythematosus characterised by deep dermal or subcutaneous nodules, most often on the head, face, or upper arms. It is generally chronic and occurs most often in women between the ages of 20 and 45. (12 Dec 1998) |
| chilblain lupus | Skin lesions seen in patients with lupus erythematosus, resembling the small, hardened nodular areas of a cold injury called chilblains. Synonym: chilblain lupus. (05 Mar 2000) |
| chilblain lupus erythematosus | Skin lesions seen in patients with lupus erythematosus, resembling the small, hardened nodular areas of a cold injury called chilblains. Synonym: chilblain lupus. (05 Mar 2000) |
| chronic discoid lupus erythematosus | A form of lupus erythematosus in which cutaneous lesions are present; these commonly appear on the face and are atrophic plaques with erythema, hyperkeratosis, follicular plugging, and telangiectasia; in some instances systemic lupus erythematosis may develop. Synonym: chronic discoid lupus erythematosus. (05 Mar 2000) |
| cutaneous lupus erythematosus | Skin disease seen in patients with discoid form of lupus erythematosus, a term for a variety of skin lesions seen in systemic lupus erythematosus. (05 Mar 2000) |
| neonatal lupus | Lupus erythematosus occurring in newborn children of mothers who had lupus during pregnancy; anti-SSA antibodies usually should be screened for; 50% have anti-nuclear antibodies. A variety of skin lesions are seen, which can resolve or leave scarring; the syndrome usually resolves; however cardiac manifestations can be fatal. Some children develop systemic lupus later in life. (05 Mar 2000) |
| systemic lupus erythematosus | <immunology, nephrology, rheumatology> A disease of humans, probably autoimmune with antinuclear and other antibodies in plasma. Immune complex deposition in the glomerular capillaries is a particular problem. Acronym: SLE (19 Jan 1998) |
| discoid lupus erythematosus | A form of lupus erythematosus in which cutaneous lesions are present; these commonly appear on the face and are atrophic plaques with erythema, hyperkeratosis, follicular plugging, and telangiectasia; in some instances systemic lupus erythematosis may develop. Synonym: chronic discoid lupus erythematosus. (05 Mar 2000) |
| disseminated lupus erythematosus | <immunology, nephrology, rheumatology> A disease of humans, probably autoimmune with antinuclear and other antibodies in plasma. Immune complex deposition in the glomerular capillaries is a particular problem. Acronym: SLE (19 Jan 1998) |
| drug-induced lupus | <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug. Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine. The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare. Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections. (18 Jul 2002) |
| lupus | A systemic disease that results from an autoimmune mechanism. Individuals with lupus will produce antibodies to their own body tissues. The resultant inflammation can cause kidney damage, arthritis, pericarditis and vasculitis. (27 Sep 1997) |
| lupus anticoagulant | An immunoglobulin that interferes with blood coagulation and has antithromboplastin activity. This immunoglobulin can prolong blood clotting and occurs in approximately 25% of people with lupus. (27 Sep 1997) |
| lupus anticoagulants | Lupus anticoagulants are a common cause of a prolonged activated partial thromboplastin time (APTT) which is corrected by the addition of platelet -rich plasma (or phospholipids) and not by platelet-poor plasma. The methods of choice for detection of lupus anticoagulants are the kaolin clotting time using the rabbit brain neutralisation procedure and the dilute Russell viper venom test (dRVVT). Current data suggest that lupus anticoagulants and antibodies to negatively charged phospholipids (cardiolipin, phosphatidylserine, phosphatidic acid and phosphatidylinositol) are risk factors for arterial and venous thrombosis and for recurrent abortions in populations of patients which are distinct but overlapping. Drug-induced lupus anticoagulants are also associated with increased risk of thrombosis. Current testing for lupus anticoagulants and phospholipid antibodies (cardiolipin plus phosphatidylserine) may be useful for assessing risk in patients with systemic lupus erythematosus. Some data indicate that lupus anticoagulants assays are more reliable predictors of thrombosis, foetal loss and thrombocytopenia than are cardiolipin antibody (ACA) assays. Although the technology is in many ways more reliable, the rush to describe associations of lupus anticoagulants with various disorders has been much less scientifically unseemly than has been that of ACAs with their bewildering variety of clinical associations. The contribution of one serious study must, it seems, render tolerable the excess of trivia recently published in this area. See also cardiolipin antibodies and phospholipid antibodies. (05 Mar 2000) |
| lupus band test | A direct immunofluorescent technique for demonstrating a band of immunoglobulins at the dermal-epidermal junction of the skin of patients with lupus erythematosus. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|